December 26, 2014 9:00 PM ET

Biotechnology

Company Overview of Savient Pharmaceuticals, Inc.

Company Overview

On May 30, 2014, Savient Pharmaceuticals, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company in the United States. It engages in developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients refractory to conventional therapy. The company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. Savient Pharmaceuticals, Inc. sells its products through a network of specialty and wholesale distributors. The company was formerly known as Bio-Technology General Corp. and...

400 Crossing Boulevard

3rd Floor

Bridgewater, NJ 08807

United States

Founded in 1980

122 Employees

Phone:

732-418-9300

Key Executives for Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. does not have any Key Executives recorded.

Savient Pharmaceuticals, Inc. Key Developments

NASDAQ To Delist Common Stock of Savient Pharmaceuticals

The NASDAQ Stock Market announced that it will delist the common stock of Savient Pharmaceuticals Inc. Savient Pharmaceuticals Inc's stock was suspended on October 17, 2013 and has not traded on NASDAQ since that time. NASDAQ will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delistings become effective ten days after the Form 25 is filed.

Savient Pharmaceuticals Receives Correspondence From The NASDAQ Hearings Coordinator

On October 8, 2013, Savient Pharmaceuticals, Inc. received a Staff Delisting Determination letter from the Listing Qualifications Staff of The NASDAQ Stock Market (“NASDAQ”) notifying the Company that it had not timely regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Global Market, as set forth in Listing Rule 5450(a)(1), and that, as a result, the Company’s securities would be subject to delisting unless the Company timely requested a hearing before the NASDAQ Hearings Panel. As the Company determined not to appeal the Staff’s determination, the Company’s common stock was suspended on October 17, 2013 and has not traded on NASDAQ since that time. On November 21, 2013, the Company received correspondence from the NASDAQ Hearings Coordinator indicating that on November 26, 2013, pursuant to its obligations under NASDAQ Listing Rule 5830 and Rule 12d2-2 of the Securities Exchange Act, the NASDAQ Stock Market will be issuing a press release announcing that it will file a Form 25 with the Securities and Exchange Commission to complete the delisting of the Company’s common stock. The delisting becomes effective ten days after the Form 25 is filed. The Company’s common stock is currently quoted on the OTCQB Marketplace (the “OTCQB”) under the symbol “SVNTQ.” However, the Company can give no assurance that trading in its common stock will continue on the OTCQB or on any other securities exchange or quotation medium.

Savient Pharmaceuticals, Inc.(NasdaqGM:SVNT) dropped from NASDAQ Composite Index

Savient Pharmaceuticals, Inc. will be removed from NASDAQ Composite Index.

Similar Private Companies By Industry

Company Name Region
Femta Pharmaceuticals, Inc. United States
Melinta Therapeutics, Inc. United States
Mytogen, Inc. United States
Igenity, Inc. United States
Novatrix Biomedical, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Savient Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.